Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Leukemia, Myeloid, Acute 7Recurrence 5Colonic Neoplasms 5Thyroid Neoplasms 4Thyroid Diseases 4Thyroid Cancer, Papillary 4Thoracic Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Neuroblastoma 4Neoplasms by Site 4Lung Neoplasms 4Lung Diseases 4Head and Neck Neoplasms 4Endocrine System Diseases 4Endocrine Gland Neoplasms 4Carcinoma, Bronchogenic 4Bronchial Neoplasms 4Breast Neoplasms 4Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Central Nervous System Neoplasms 3Carcinoma, Medullary 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2

Interventions

ibrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Has announcements × Bronchiolitis Obliterans Syndrome × Clear all
NCT03790332 2025-10-21

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Pharmacyclics LLC.

Phase 1/2 Completed
59 enrolled 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT02195869 2019-07-11

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Pharmacyclics LLC.

Phase 1/2 Completed
45 enrolled 13 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡